Teva Pharmaceutical Industries Ltd. — Director's Dealing 2024

Mar 5, 2024

FORM 4 Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b). Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(th) of the Investment Company Act of 1940

(Print or Type Responses)
1. Name and Address of Reporting Person Sabag Mark			2. Issuer Name and Ticker or Trading Symbol Teva Pharmaceutical Industries Limited TEVA	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner
(Last) 124 Dvora HaNevi'a St.,	(First) C/O Teva Pharmaceutical Industries Ltd.	(Middle)	3. Date of Earliest Transaction (Month/Day/Year) 03/03/2024	X __ Officer (give title below) Other (specify below) EVP, International Markets
(Street) Tel Aviv, L3 6944020			4. If Amendment, Date Original Filed (Month/Day/Year)	6. Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person Form filed by More than One Reporting Person
(City)	(State)	(Zip)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1.Title of Security	2. Transaction	2A. Deemed	3. Transaction		4. Securities Acquired			5. Amount of Securities Beneficially		7. Nature
(Instr. 3)	Date	l Execution Date, if Code			(A) or Disposed of (D)			Owned Following Reported	Ownership of Indirect
	(Month/Day/Year) any		(Instr. 8)		(Instr. 3, 4 and 5)			Transaction(s)	Form:	Beneficial
		ا (Month/Day/Year)						(Instr. 3 and 4)		Direct (D) Ownership
									or Indirect	(Instr. 4)
						(A) or			(1)
			Code		Amount	D)	Price		(Instr. 4)
'Ordinary Shares (1)	03/03/2024		M		24,900	A	(2)	367,181	D
'Ordinary Shares (1)	03/04/2024		M		33,512	A	(2)	400.693	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
e.g. , puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2 Conversion Date Price of Derivative Security	3. Transaction or Exercise (Month/Day/Year) any	3A. Deemed Execution Date, if Transaction Derivative (Month/Day/Year) (Instr. 8)	4. Code	1 - 0 - 7 1 - 1 - 1 - 1 - 1 - 1 - 1 - 1 - 1 - 1 - 1 - 1 - 1 - 1 - 1 - 1 - 1 - 1 - 1 - 1 - 1 - 1 - 1 - 1 - 1 - 1 - 1 - 1 - 1 - 1 - 1 - 1 - 1 - 1 - 1 - 1 - 1 - 1 - 1 - 1 - 1 - 5. Number of Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)			6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Underlying Securities (Instr. 3 and 4)		Derivative Derivative Security (Instr. 5)	8. Price of 9. Number of Securities Beneficially Owned Following	10 Ownership of Indirect Form of Derivative Security: Direct (D)	11. Nature Beneficial Ownership (Instr. 4)
				Code		(A)	(D)	Date Exercisable Date	Expiration	Reported Amount or Title Number of Shares		Transaction(s) (Instr. 4)	or Indirect (1) (Instr. 4)
Restricted Share Units	(2)	03/03/2024		M			24,900	(3)	(3)	Ordinary Shares (1)	24,900	\$ 0	74,701	D
Restricted Share Units	(2)	03/04/2024		M			33,512	(4)	(4)	Ordinary Shares (1)	33,512	\$ 0	67,024	D
Restricted Share Units	(2)	03/04/2024		A		74,404		(5)	(5)	Ordinary Shares (1)	74,404	\$ 0	74,404	D

Explanation of Responses:

1. The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

2. 1. Each restricted share unit represents a continent, one ordinary share or at the option of the Human Resources and Compensation Committee, the cash valle of one ordinary share.
3. 1. Restricted share mits were granted on March 3, 2024, March 3, 2024, March 3, 2024, March 3, 2026, and 24,90 vesing on March 3, 2027.
4. 1. Restricted share units were grantel on March 4, 2022, with 3,512 vesting on each of March 4, 2025 and 3,512 vesting on each of March 4, 2026,
5. 1. Restricted share units were granted on March 4, 2024, with 18,601 vesting on each of March 4, 2026, March 4, 2027, and March 4, 2028,

Signatures

/s/ Dov Bergwerk as attorney-in-fact for Mark Sabag 03/05/2024

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly.

• * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
• ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 18tf(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of in this form are not required to respond unless the form displays a currently valid OMB Number.